JP2011509992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509992A5 JP2011509992A5 JP2010542694A JP2010542694A JP2011509992A5 JP 2011509992 A5 JP2011509992 A5 JP 2011509992A5 JP 2010542694 A JP2010542694 A JP 2010542694A JP 2010542694 A JP2010542694 A JP 2010542694A JP 2011509992 A5 JP2011509992 A5 JP 2011509992A5
- Authority
- JP
- Japan
- Prior art keywords
- triazine
- diamino
- compound
- carbons
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- -1 phenoxy, naphthyl Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- LUZDYPLAQQGJEA-UHFFFAOYSA-N 2-Methoxynaphthalene Chemical compound C1=CC=CC2=CC(OC)=CC=C21 LUZDYPLAQQGJEA-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- ZYIQXLMCVLLFOK-UHFFFAOYSA-N 6-(9h-xanthen-9-yl)-1,2,4-triazine-3,5-diamine Chemical compound NC1=NC(N)=NN=C1C1C2=CC=CC=C2OC2=CC=CC=C21 ZYIQXLMCVLLFOK-UHFFFAOYSA-N 0.000 claims 1
- KOFUQZSRVDQEPT-UHFFFAOYSA-N 6-[1-(4-chlorophenyl)cyclobutyl]-1,2,4-triazine-3,5-diamine Chemical compound NC1=NC(N)=NN=C1C1(C=2C=CC(Cl)=CC=2)CCC1 KOFUQZSRVDQEPT-UHFFFAOYSA-N 0.000 claims 1
- PGIVWZKAAUFMPE-UHFFFAOYSA-N 6-[1-(4-chlorophenyl)cyclohexyl]-1,2,4-triazine-3,5-diamine Chemical compound NC1=NC(N)=NN=C1C1(C=2C=CC(Cl)=CC=2)CCCCC1 PGIVWZKAAUFMPE-UHFFFAOYSA-N 0.000 claims 1
- AYSCDGDHONEJNC-UHFFFAOYSA-N 6-[1-(4-chlorophenyl)cyclopentyl]-1,2,4-triazine-3,5-diamine Chemical compound NC1=NC(N)=NN=C1C1(C=2C=CC(Cl)=CC=2)CCCC1 AYSCDGDHONEJNC-UHFFFAOYSA-N 0.000 claims 1
- JYZNXIHTIVXYJZ-UHFFFAOYSA-N 6-[1-(4-chlorophenyl)cyclopropyl]-1,2,4-triazine-3,5-diamine Chemical compound NC1=NC(N)=NN=C1C1(C=2C=CC(Cl)=CC=2)CC1 JYZNXIHTIVXYJZ-UHFFFAOYSA-N 0.000 claims 1
- DBVJIAPQCSTRRE-UHFFFAOYSA-N 6-[bis(4-chlorophenyl)methyl]-1,2,4-triazine-3,5-diamine Chemical compound NC1=NC(N)=NN=C1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 DBVJIAPQCSTRRE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 210000000467 autonomic pathway Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0800741.1 | 2008-01-16 | ||
| GBGB0800741.1A GB0800741D0 (en) | 2008-01-16 | 2008-01-16 | Cyclic triazo and diazo sodium channel blockers |
| PCT/GB2009/050033 WO2009090431A1 (en) | 2008-01-16 | 2009-01-16 | Cyclic triazo and diazo sodium channel blockers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509992A JP2011509992A (ja) | 2011-03-31 |
| JP2011509992A5 true JP2011509992A5 (enExample) | 2012-03-01 |
| JP5473944B2 JP5473944B2 (ja) | 2014-04-16 |
Family
ID=39144997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542694A Active JP5473944B2 (ja) | 2008-01-16 | 2009-01-16 | 環式トリアゾおよびジアゾナトリウムチャネル遮断薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8691818B2 (enExample) |
| EP (2) | EP3002280B1 (enExample) |
| JP (1) | JP5473944B2 (enExample) |
| KR (1) | KR101600636B1 (enExample) |
| CN (2) | CN103705519B (enExample) |
| AU (1) | AU2009205396B2 (enExample) |
| CA (1) | CA2712070C (enExample) |
| ES (2) | ES2565023T3 (enExample) |
| GB (1) | GB0800741D0 (enExample) |
| IL (1) | IL206815A (enExample) |
| WO (1) | WO2009090431A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| GB2471729A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| GB2471713A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| US8809525B2 (en) * | 2010-02-05 | 2014-08-19 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
| WO2012019106A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| CN104341386A (zh) * | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途 |
| US10576086B2 (en) * | 2015-06-12 | 2020-03-03 | University Of Greenwich | Triazine derivatives as interferon-gamma inhibitors |
| AU2018302178A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| WO2019018584A1 (en) * | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| CN107915633A (zh) * | 2017-12-06 | 2018-04-17 | 安徽绩溪县徽煌化工有限公司 | 一种间苄氧基苯甲酸甲酯的制备方法 |
| PL424999A1 (pl) * | 2018-03-22 | 2019-09-23 | Glg Pharma Spółka Akcyjna | Farmaceutycznie akceptowalna sól 5-(4-chlorofenylo)-6-etylo-2,4- pirymidynodiaminy |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| KR20210116550A (ko) | 2019-01-18 | 2021-09-27 | 누베이션 바이오 인크. | 아데노신 길항제로서의 헤테로시클릭 화합물 |
| GB202006076D0 (en) | 2020-04-24 | 2020-06-10 | Univ Greenwich | Interleukin inhibitors |
| GB202006080D0 (en) | 2020-04-24 | 2020-06-10 | Univ Greenwich | Cytokine storm syndrome |
| CA3199909A1 (en) * | 2020-11-23 | 2022-05-27 | Steven HOCHWALD | Compounds and methods to target glucose-stimulated phosphohistidine signaling and esophageal cancer growth |
| KR20250030934A (ko) * | 2023-08-25 | 2025-03-05 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB759014A (en) | 1952-02-26 | 1956-10-10 | Wellcome Found | Improvements in triazines and their manufacture |
| US3637688A (en) * | 1970-01-09 | 1972-01-25 | American Home Prod | 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines |
| JPS5625170A (en) * | 1979-06-01 | 1981-03-10 | Wellcome Found | Triazine derivative |
| CA1133938A (en) * | 1979-06-01 | 1982-10-19 | Martin G. Baxter | Substituted aromatic compounds |
| IE49823B1 (en) * | 1979-06-01 | 1985-12-25 | Wellcome Found | 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them |
| DE3069556D1 (en) * | 1979-08-16 | 1984-12-06 | Wellcome Found | Solid pharmaceutical formulation containing substitued phenyl-triazines |
| GB8328757D0 (en) * | 1983-10-27 | 1983-11-30 | Wellcome Found | Chemical compounds |
| FI895821A7 (fi) | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| GB9012312D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| US5502054A (en) * | 1994-08-11 | 1996-03-26 | Fmc Corporation | 6-substituted-3,5-diamino-1,2,4-triazines as insecticides |
| MA26473A1 (fr) | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
| DE10134980C2 (de) * | 2001-07-17 | 2003-05-28 | Helm Ag | Verfahren zur Herstellung von Lamotrigin |
| HU225667B1 (en) | 2002-09-20 | 2007-05-29 | Richter Gedeon Nyrt | Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine |
| GB0300783D0 (en) * | 2003-01-14 | 2003-02-12 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| GB0613836D0 (en) * | 2006-07-13 | 2006-08-23 | Univ Greenwich | New medical use of triazine derivatives |
| GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| GB2471713A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| GB2471729A (en) * | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
-
2008
- 2008-01-16 GB GBGB0800741.1A patent/GB0800741D0/en not_active Ceased
-
2009
- 2009-01-16 ES ES09701748.7T patent/ES2565023T3/es active Active
- 2009-01-16 EP EP15185526.9A patent/EP3002280B1/en active Active
- 2009-01-16 US US12/811,884 patent/US8691818B2/en active Active
- 2009-01-16 JP JP2010542694A patent/JP5473944B2/ja active Active
- 2009-01-16 CN CN201310579107.1A patent/CN103705519B/zh active Active
- 2009-01-16 ES ES15185526T patent/ES2953286T3/es active Active
- 2009-01-16 AU AU2009205396A patent/AU2009205396B2/en active Active
- 2009-01-16 WO PCT/GB2009/050033 patent/WO2009090431A1/en not_active Ceased
- 2009-01-16 CA CA2712070A patent/CA2712070C/en active Active
- 2009-01-16 CN CN2009801023991A patent/CN101918378B/zh active Active
- 2009-01-16 KR KR1020107017361A patent/KR101600636B1/ko not_active Expired - Fee Related
- 2009-01-16 EP EP09701748.7A patent/EP2229371B1/en active Active
-
2010
- 2010-07-05 IL IL206815A patent/IL206815A/en active IP Right Grant
-
2014
- 2014-02-06 US US14/174,492 patent/US9422253B2/en active Active
-
2016
- 2016-07-05 US US15/201,885 patent/US9862691B2/en active Active